Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Emerging SARS-CoV-2 variant BA.3.2 shows no signs of greater danger

3

Apr 2026

Emerging SARS-CoV-2 variant BA.3.2 shows no signs of greater danger

The Global Virus Network (GVN), representing eminent human and animal virologists from more than 90 Centers of Excellence and Affiliates in over 40 countries dedicated to advancing research, collaboration, and pandemic preparedness, is monitoring the SARS-CoV-2 variant BA.3.2, sometimes informally referred to in media reports as the "cicada" variant, and emphasizes that current evidence does not indicate cause for alarm or heightened public concern.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.